Use of Technetium‐99m‐Pyrophosphate Single‐Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy

Hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a tool to monitor the effectiveness of hATTR-CM treatment. The objective of this study was to examine how eplontersen therapy influences the se...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American Heart Association Vol. 13; no. 2; p. e030512
Main Authors Yu, An‐Li, Chen, Yi‐Chieh, Tsai, Cheng‐Hsuan, Wu, Yuan‐Kun Aden, Su, Mao‐Yuan, Chou, Chia‐Hung, Shun, Chia‐Tung, Hsueh, Hsueh‐Wen, Juang, Jimmy Jyh‐Ming, Lee, Ming‐Jen, Tseng, Ping‐Huei, Hsu, Chia‐Hua, Hsieh, Sung‐Tsang, Ko, Chi‐Lun, Cheng, Mei‐Fang, Chao, Chi‐Chao, Lin, Yen‐Hung
Format Journal Article
LanguageEnglish
Published England John Wiley and Sons Inc 16.01.2024
Wiley
Subjects
99mTc‐pyrophosphate
eplontersen
hereditary transthyretin amyloidosis
Original Research
single‐photon emission computed tomography/computed tomography
99mTc‐pyrophosphate
hereditary transthyretin amyloidosis
eplontersen
single‐photon emission computed tomography/computed tomography
Online AccessGet full text

Cover

Abstract Hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a tool to monitor the effectiveness of hATTR-CM treatment. The objective of this study was to examine how eplontersen therapy influences the semiquantitative uptake of technetium-99m-pyrophosphate in individuals diagnosed with hATTR-CM. We retrospectively analyzed a prospective cohort from the NEURO-TTRansform trial, including patients with hATTR-CM receiving eplontersen (45 mg/4 weeks). A control group comprised patients with hATTR-CM who had not received eplontersen, inotersen, tafamidis, or patisiran. Technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography was conducted at baseline and during follow-up. Thirteen patients with hATTR-CM were enrolled, with 6 receiving eplontersen and 7 serving as the control group. The median follow-up time was 544 days. The eplontersen group exhibited a significant decrease in volumetric heart and lung ratio (3.774 to 2.979, =0.028), whereas the control group showed no significant change (4.079 to 3.915, =0.237). Patients receiving eplontersen demonstrated a significantly greater reduction in volumetric heart and lung ratio compared with the control group (-20.7% versus -3.4%, =0.007). The volumetric heart and lung ratio used to quantify technetium-99m-pyrophosphate uptake showed a significant reduction subsequent to eplontersen treatment in individuals diagnosed with hATTR-CM. These findings suggest the potential efficacy of eplontersen in treating hATTR-CM and highlight the value of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography as a tool for monitoring therapeutic effectiveness.
AbstractList Hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a tool to monitor the effectiveness of hATTR-CM treatment. The objective of this study was to examine how eplontersen therapy influences the semiquantitative uptake of technetium-99m-pyrophosphate in individuals diagnosed with hATTR-CM.BACKGROUNDHereditary transthyretin amyloid cardiomyopathy (hATTR-CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a tool to monitor the effectiveness of hATTR-CM treatment. The objective of this study was to examine how eplontersen therapy influences the semiquantitative uptake of technetium-99m-pyrophosphate in individuals diagnosed with hATTR-CM.We retrospectively analyzed a prospective cohort from the NEURO-TTRansform trial, including patients with hATTR-CM receiving eplontersen (45 mg/4 weeks). A control group comprised patients with hATTR-CM who had not received eplontersen, inotersen, tafamidis, or patisiran. Technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography was conducted at baseline and during follow-up. Thirteen patients with hATTR-CM were enrolled, with 6 receiving eplontersen and 7 serving as the control group. The median follow-up time was 544 days. The eplontersen group exhibited a significant decrease in volumetric heart and lung ratio (3.774 to 2.979, P=0.028), whereas the control group showed no significant change (4.079 to 3.915, P=0.237). Patients receiving eplontersen demonstrated a significantly greater reduction in volumetric heart and lung ratio compared with the control group (-20.7% versus -3.4%, P=0.007).METHODS AND RESULTSWe retrospectively analyzed a prospective cohort from the NEURO-TTRansform trial, including patients with hATTR-CM receiving eplontersen (45 mg/4 weeks). A control group comprised patients with hATTR-CM who had not received eplontersen, inotersen, tafamidis, or patisiran. Technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography was conducted at baseline and during follow-up. Thirteen patients with hATTR-CM were enrolled, with 6 receiving eplontersen and 7 serving as the control group. The median follow-up time was 544 days. The eplontersen group exhibited a significant decrease in volumetric heart and lung ratio (3.774 to 2.979, P=0.028), whereas the control group showed no significant change (4.079 to 3.915, P=0.237). Patients receiving eplontersen demonstrated a significantly greater reduction in volumetric heart and lung ratio compared with the control group (-20.7% versus -3.4%, P=0.007).The volumetric heart and lung ratio used to quantify technetium-99m-pyrophosphate uptake showed a significant reduction subsequent to eplontersen treatment in individuals diagnosed with hATTR-CM. These findings suggest the potential efficacy of eplontersen in treating hATTR-CM and highlight the value of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography as a tool for monitoring therapeutic effectiveness.CONCLUSIONSThe volumetric heart and lung ratio used to quantify technetium-99m-pyrophosphate uptake showed a significant reduction subsequent to eplontersen treatment in individuals diagnosed with hATTR-CM. These findings suggest the potential efficacy of eplontersen in treating hATTR-CM and highlight the value of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography as a tool for monitoring therapeutic effectiveness.
Hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a tool to monitor the effectiveness of hATTR-CM treatment. The objective of this study was to examine how eplontersen therapy influences the semiquantitative uptake of technetium-99m-pyrophosphate in individuals diagnosed with hATTR-CM. We retrospectively analyzed a prospective cohort from the NEURO-TTRansform trial, including patients with hATTR-CM receiving eplontersen (45 mg/4 weeks). A control group comprised patients with hATTR-CM who had not received eplontersen, inotersen, tafamidis, or patisiran. Technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography was conducted at baseline and during follow-up. Thirteen patients with hATTR-CM were enrolled, with 6 receiving eplontersen and 7 serving as the control group. The median follow-up time was 544 days. The eplontersen group exhibited a significant decrease in volumetric heart and lung ratio (3.774 to 2.979, =0.028), whereas the control group showed no significant change (4.079 to 3.915, =0.237). Patients receiving eplontersen demonstrated a significantly greater reduction in volumetric heart and lung ratio compared with the control group (-20.7% versus -3.4%, =0.007). The volumetric heart and lung ratio used to quantify technetium-99m-pyrophosphate uptake showed a significant reduction subsequent to eplontersen treatment in individuals diagnosed with hATTR-CM. These findings suggest the potential efficacy of eplontersen in treating hATTR-CM and highlight the value of technetium-99m-pyrophosphate single-photon emission computed tomography/computed tomography as a tool for monitoring therapeutic effectiveness.
Background Hereditary transthyretin amyloid cardiomyopathy (hATTR‐CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a tool to monitor the effectiveness of hATTR‐CM treatment. The objective of this study was to examine how eplontersen therapy influences the semiquantitative uptake of technetium‐99m‐pyrophosphate in individuals diagnosed with hATTR‐CM. Methods and Results We retrospectively analyzed a prospective cohort from the NEURO‐TTRansform trial, including patients with hATTR‐CM receiving eplontersen (45 mg/4 weeks). A control group comprised patients with hATTR‐CM who had not received eplontersen, inotersen, tafamidis, or patisiran. Technetium‐99m‐pyrophosphate single‐photon emission computed tomography/computed tomography was conducted at baseline and during follow‐up. Thirteen patients with hATTR‐CM were enrolled, with 6 receiving eplontersen and 7 serving as the control group. The median follow‐up time was 544 days. The eplontersen group exhibited a significant decrease in volumetric heart and lung ratio (3.774 to 2.979, P=0.028), whereas the control group showed no significant change (4.079 to 3.915, P=0.237). Patients receiving eplontersen demonstrated a significantly greater reduction in volumetric heart and lung ratio compared with the control group (−20.7% versus −3.4%, P=0.007). Conclusions The volumetric heart and lung ratio used to quantify technetium‐99m‐pyrophosphate uptake showed a significant reduction subsequent to eplontersen treatment in individuals diagnosed with hATTR‐CM. These findings suggest the potential efficacy of eplontersen in treating hATTR‐CM and highlight the value of technetium‐99m‐pyrophosphate single‐photon emission computed tomography/computed tomography as a tool for monitoring therapeutic effectiveness.
Author Chen, Yi‐Chieh
Chao, Chi‐Chao
Lin, Yen‐Hung
Hsueh, Hsueh‐Wen
Tseng, Ping‐Huei
Shun, Chia‐Tung
Juang, Jimmy Jyh‐Ming
Wu, Yuan‐Kun Aden
Hsieh, Sung‐Tsang
Cheng, Mei‐Fang
Yu, An‐Li
Chou, Chia‐Hung
Hsu, Chia‐Hua
Ko, Chi‐Lun
Lee, Ming‐Jen
Tsai, Cheng‐Hsuan
Su, Mao‐Yuan
AuthorAffiliation 11 Institute of Environmental and Occupational Health Sciences National Taiwan University Taipei Taiwan
6 Department of Medical Imaging and Radiological Technology Yuanpei University of Medical Technology Hsinchu Taiwan
8 Department of Forensic Medicine and Pathology National Taiwan University Hospital Taipei Taiwan
2 Department of Internal Medicine, Division of Cardiology National Taiwan University Hospital Hsin‐Chu Branch Hsinchu Taiwan
4 National Taiwan University College of Medicine Graduate Institute of Clinical Medicine Taipei Taiwan
9 Department of Neurology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
7 Department of Obstetrics and Gynecology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
5 Department of Medical Imaging National Taiwan University Hospital Taipei Taiwan
10 Department of Internal Medicine, Division of Gastroenterology National Taiwan University Hospital and Natio
AuthorAffiliation_xml – name: 6 Department of Medical Imaging and Radiological Technology Yuanpei University of Medical Technology Hsinchu Taiwan
– name: 7 Department of Obstetrics and Gynecology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– name: 4 National Taiwan University College of Medicine Graduate Institute of Clinical Medicine Taipei Taiwan
– name: 11 Institute of Environmental and Occupational Health Sciences National Taiwan University Taipei Taiwan
– name: 1 Department of Internal Medicine, Division of Cardiology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– name: 8 Department of Forensic Medicine and Pathology National Taiwan University Hospital Taipei Taiwan
– name: 10 Department of Internal Medicine, Division of Gastroenterology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– name: 2 Department of Internal Medicine, Division of Cardiology National Taiwan University Hospital Hsin‐Chu Branch Hsinchu Taiwan
– name: 5 Department of Medical Imaging National Taiwan University Hospital Taipei Taiwan
– name: 3 Department of Nuclear Medicine National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– name: 9 Department of Neurology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
Author_xml – sequence: 1
  givenname: An‐Li
  orcidid: 0000-0001-5512-9395
  surname: Yu
  fullname: Yu, An‐Li
  organization: Department of Internal Medicine, Division of Cardiology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan, Department of Internal Medicine, Division of Cardiology National Taiwan University Hospital Hsin‐Chu Branch Hsinchu Taiwan
– sequence: 2
  givenname: Yi‐Chieh
  surname: Chen
  fullname: Chen, Yi‐Chieh
  organization: Department of Nuclear Medicine National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– sequence: 3
  givenname: Cheng‐Hsuan
  orcidid: 0000-0003-2859-5117
  surname: Tsai
  fullname: Tsai, Cheng‐Hsuan
  organization: Department of Internal Medicine, Division of Cardiology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan, National Taiwan University College of Medicine Graduate Institute of Clinical Medicine Taipei Taiwan
– sequence: 4
  givenname: Yuan‐Kun Aden
  surname: Wu
  fullname: Wu, Yuan‐Kun Aden
  organization: Department of Internal Medicine, Division of Cardiology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– sequence: 5
  givenname: Mao‐Yuan
  orcidid: 0000-0002-6699-2298
  surname: Su
  fullname: Su, Mao‐Yuan
  organization: Department of Medical Imaging National Taiwan University Hospital Taipei Taiwan, Department of Medical Imaging and Radiological Technology Yuanpei University of Medical Technology Hsinchu Taiwan
– sequence: 6
  givenname: Chia‐Hung
  surname: Chou
  fullname: Chou, Chia‐Hung
  organization: Department of Obstetrics and Gynecology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– sequence: 7
  givenname: Chia‐Tung
  orcidid: 0000-0002-0468-4468
  surname: Shun
  fullname: Shun, Chia‐Tung
  organization: Department of Forensic Medicine and Pathology National Taiwan University Hospital Taipei Taiwan
– sequence: 8
  givenname: Hsueh‐Wen
  orcidid: 0000-0003-4707-1861
  surname: Hsueh
  fullname: Hsueh, Hsueh‐Wen
  organization: Department of Neurology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– sequence: 9
  givenname: Jimmy Jyh‐Ming
  orcidid: 0000-0003-4767-7636
  surname: Juang
  fullname: Juang, Jimmy Jyh‐Ming
  organization: Department of Internal Medicine, Division of Cardiology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– sequence: 10
  givenname: Ming‐Jen
  surname: Lee
  fullname: Lee, Ming‐Jen
  organization: Department of Neurology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– sequence: 11
  givenname: Ping‐Huei
  surname: Tseng
  fullname: Tseng, Ping‐Huei
  organization: Department of Internal Medicine, Division of Gastroenterology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– sequence: 12
  givenname: Chia‐Hua
  orcidid: 0009-0000-3720-9607
  surname: Hsu
  fullname: Hsu, Chia‐Hua
  organization: Department of Neurology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– sequence: 13
  givenname: Sung‐Tsang
  orcidid: 0000-0002-3188-8482
  surname: Hsieh
  fullname: Hsieh, Sung‐Tsang
  organization: Department of Neurology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– sequence: 14
  givenname: Chi‐Lun
  surname: Ko
  fullname: Ko, Chi‐Lun
  organization: Department of Nuclear Medicine National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– sequence: 15
  givenname: Mei‐Fang
  orcidid: 0000-0002-9359-0606
  surname: Cheng
  fullname: Cheng, Mei‐Fang
  organization: Department of Nuclear Medicine National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan, Institute of Environmental and Occupational Health Sciences National Taiwan University Taipei Taiwan
– sequence: 16
  givenname: Chi‐Chao
  orcidid: 0000-0001-6499-5789
  surname: Chao
  fullname: Chao, Chi‐Chao
  organization: Department of Neurology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
– sequence: 17
  givenname: Yen‐Hung
  orcidid: 0000-0001-8153-1441
  surname: Lin
  fullname: Lin, Yen‐Hung
  organization: Department of Internal Medicine, Division of Cardiology National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38214277$$D View this record in MEDLINE/PubMed
BookMark eNp1UsFu1DAQjVARLaVnbshHLrtrO3ESn9BqtbBFRVRiK46W40w2rhI72A5SbnwC38eRL8FhS9Ui8MEejd-8eaN5z5MTYw0kyUuCl4TkZPV-vVsvCU2XOMWM0CfJGcVZseC8xCcP4tPkwvtbHE9Oi5TxZ8lpWlKS0aI4S37ceEC2QXtQrYGgx_7nt--cz_f15OzQWj-0MgD6pM2hgznd2mAN2vbaex2Dje2HMUCN9ra3ByeHdlr9I4e0QR-s0cG6yIT2LcQ0jEErtGmlOYCfZWyHzpoAzoOZC65l0GCCR591aNEOHNQ6SDehvZPGh3ZyUbJB637qrK7RRrpa236yg4x_L5Knjew8XNy958nN2-1-s1tcfXx3uVlfLVSW47DISdU0quEZzuoC5wVvqrSWWakoBlw3GZOVoryCJiVQlQ1gXIEioCqekZwxnJ4nl0fe2spbMTjdR4XCSi1-J6w7COninB2IOsuBV3FZFaGZxGnJak4bpgjHDOdlFbneHLmGseqhVnF4J7tHpI9_jG7FwX4VBHOalziNDK_vGJz9MoIPIi5KQddJA3b0gnLCWEEIoxH66mGz-y5_3BEBqyNAOeu9g-YeQrCYLShmC4poQXG0YKxgf1WouLAQfRLV6u6_db8ADuTpaw
CitedBy_id crossref_primary_10_1097_HCO_0000000000001156
crossref_primary_10_3390_diagnostics14192249
crossref_primary_10_3390_ijms26010146
crossref_primary_10_1007_s00259_025_07079_4
crossref_primary_10_1097_MD_0000000000038767
crossref_primary_10_7759_cureus_62981
crossref_primary_10_1161_CIRCULATIONAHA_124_066522
crossref_primary_10_1007_s11886_025_02202_1
crossref_primary_10_1016_j_jfma_2024_10_005
Cites_doi 10.1016/j.jacc.2019.04.003
10.1001/jamacardio.2016.2839
10.1056/NEJMoa1805689
10.1016/j.cjca.2019.12.033
10.1093/eurheartj/ehx589
10.1007/s12350-018-01552-4
10.1016/j.jns.2019.116424
10.1161/01.CIR.55.4.613
10.1161/HCI.0000000000000029
10.1080/13506129.2019.1582479
10.1161/CIRCULATIONAHA.118.038169
10.1186/s13023-021-01706-7
10.1186/s12883-021-02243-3
10.1016/j.jacc.2015.09.075
10.1161/CIRCIMAGING.112.000132
10.1111/jns.12153
10.1002/ehf2.14165
10.1185/03007995.2012.754348
10.1002/acn3.778
10.1007/s12350-015-0261-x
10.7326/0003-4819-145-4-200608150-00004
10.1016/j.jcmg.2022.12.016
10.1002/ehf2.13154
10.1002/ajh.20381
10.1038/nrcardio.2010.67
10.1080/13506129.2021.1991302
10.1038/s41582-019-0210-4
10.1093/ehjci/jeab111.058
10.1007/s40120-022-00414-z
10.1093/ehjci/jev014
10.1161/CIRCULATIONAHA.116.024438
10.1016/j.jcmg.2020.07.043
10.1161/CIRCULATIONAHA.116.021612
10.1111/j.1523-1755.2004.00971.x
10.1136/jnnp-2014-308724
10.1016/j.jcmg.2022.06.013
10.1016/j.jaccas.2020.11.036
10.1002/ehf2.12989
10.1016/j.jacc.2013.02.059
10.1161/CIRCIMAGING.123.015243
10.1161/HCI.0000000000000030
10.1002/acn3.51328
10.1007/s40120-021-00235-6
10.1253/circj.CJ-20-0110
ContentType Journal Article
Copyright 2024 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
Copyright_xml – notice: 2024 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.1161/JAHA.123.030512
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals - May need to register for free articles
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Monitoring Effectiveness of Eplontersen by Tc‐PYP
EISSN 2047-9980
ExternalDocumentID oai_doaj_org_article_d46e9b051b124a0385d92f5c1905068b
PMC10926803
38214277
10_1161_JAHA_123_030512
Genre Journal Article
GroupedDBID 0R~
1OC
24P
53G
5VS
8-1
AAYXX
AAZKR
ACCMX
ACGFO
ACXQS
ADBBV
ADKYN
ADZMN
AEGXH
AENEX
AIAGR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AVUZU
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GODZA
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
RAH
RNS
RPM
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
NPM
7X8
5PM
WIN
ID FETCH-LOGICAL-c460t-61bffcf9404d70679fb3da48c20e0df45abc29bef31eb8fe00bec1ecb94165503
IEDL.DBID M48
ISSN 2047-9980
IngestDate Wed Aug 27 01:28:01 EDT 2025
Thu Aug 21 18:35:02 EDT 2025
Thu Jul 10 18:24:51 EDT 2025
Mon Jul 21 06:04:35 EDT 2025
Tue Jul 01 03:15:38 EDT 2025
Thu Apr 24 23:02:24 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords 99mTc‐pyrophosphate
hereditary transthyretin amyloidosis
eplontersen
single‐photon emission computed tomography/computed tomography
Language English
License This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c460t-61bffcf9404d70679fb3da48c20e0df45abc29bef31eb8fe00bec1ecb94165503
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was sent to Barry London, MD, PhD, Senior Guest Editor, for review by expert referees, editorial decision, and final disposition.
For Sources of Funding and Disclosures, see page 9.
M.‐F. Cheng and C.‐C. Chao contributed equally.
ORCID 0000-0001-8153-1441
0000-0003-2859-5117
0000-0002-6699-2298
0000-0002-0468-4468
0000-0002-3188-8482
0000-0002-9359-0606
0000-0003-4707-1861
0000-0001-5512-9395
0000-0003-4767-7636
0009-0000-3720-9607
0000-0001-6499-5789
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1161/JAHA.123.030512
PMID 38214277
PQID 2915571152
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_d46e9b051b124a0385d92f5c1905068b
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10926803
proquest_miscellaneous_2915571152
pubmed_primary_38214277
crossref_primary_10_1161_JAHA_123_030512
crossref_citationtrail_10_1161_JAHA_123_030512
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-01-16
PublicationDateYYYYMMDD 2024-01-16
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-01-16
  day: 16
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Hoboken
PublicationTitle Journal of the American Heart Association
PublicationTitleAlternate J Am Heart Assoc
PublicationYear 2024
Publisher John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley and Sons Inc
– name: Wiley
References e_1_3_2_26_2
e_1_3_2_27_2
e_1_3_2_28_2
e_1_3_2_29_2
e_1_3_2_41_2
e_1_3_2_40_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_24_2
e_1_3_2_47_2
e_1_3_2_25_2
e_1_3_2_46_2
e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_30_2
e_1_3_2_32_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_2_2
e_1_3_2_14_2
e_1_3_2_35_2
Doumas A (e_1_3_2_19_2) 2022; 25
References_xml – ident: e_1_3_2_11_2
  doi: 10.1016/j.jacc.2019.04.003
– ident: e_1_3_2_13_2
  doi: 10.1001/jamacardio.2016.2839
– ident: e_1_3_2_25_2
  doi: 10.1056/NEJMoa1805689
– ident: e_1_3_2_4_2
  doi: 10.1016/j.cjca.2019.12.033
– ident: e_1_3_2_30_2
  doi: 10.1093/eurheartj/ehx589
– ident: e_1_3_2_39_2
  doi: 10.1007/s12350-018-01552-4
– ident: e_1_3_2_24_2
  doi: 10.1016/j.jns.2019.116424
– ident: e_1_3_2_33_2
  doi: 10.1161/01.CIR.55.4.613
– ident: e_1_3_2_35_2
  doi: 10.1161/HCI.0000000000000029
– ident: e_1_3_2_44_2
  doi: 10.1080/13506129.2019.1582479
– ident: e_1_3_2_9_2
  doi: 10.1161/CIRCULATIONAHA.118.038169
– ident: e_1_3_2_10_2
  doi: 10.1186/s13023-021-01706-7
– ident: e_1_3_2_45_2
  doi: 10.1186/s12883-021-02243-3
– ident: e_1_3_2_6_2
  doi: 10.1016/j.jacc.2015.09.075
– ident: e_1_3_2_12_2
  doi: 10.1161/CIRCIMAGING.112.000132
– ident: e_1_3_2_7_2
  doi: 10.1111/jns.12153
– ident: e_1_3_2_20_2
  doi: 10.1002/ehf2.14165
– ident: e_1_3_2_2_2
  doi: 10.1185/03007995.2012.754348
– ident: e_1_3_2_42_2
  doi: 10.1002/acn3.778
– ident: e_1_3_2_38_2
  doi: 10.1007/s12350-015-0261-x
– ident: e_1_3_2_29_2
  doi: 10.7326/0003-4819-145-4-200608150-00004
– ident: e_1_3_2_21_2
  doi: 10.1016/j.jcmg.2022.12.016
– ident: e_1_3_2_22_2
  doi: 10.1002/ehf2.13154
– ident: e_1_3_2_26_2
  doi: 10.1002/ajh.20381
– ident: e_1_3_2_37_2
  doi: 10.1038/nrcardio.2010.67
– ident: e_1_3_2_40_2
  doi: 10.1080/13506129.2021.1991302
– ident: e_1_3_2_3_2
  doi: 10.1038/s41582-019-0210-4
– ident: e_1_3_2_18_2
  doi: 10.1093/ehjci/jeab111.058
– ident: e_1_3_2_46_2
  doi: 10.1007/s40120-022-00414-z
– volume: 25
  start-page: 216
  year: 2022
  ident: e_1_3_2_19_2
  article-title: A novel quantitative method for assessing the therapeutic response to tafamidis therapy in patients with cardiac TTR amyloidosis. A preliminary report
  publication-title: Hell J Nucl Med
– ident: e_1_3_2_32_2
  doi: 10.1093/ehjci/jev014
– ident: e_1_3_2_28_2
  doi: 10.1161/CIRCULATIONAHA.116.024438
– ident: e_1_3_2_16_2
  doi: 10.1016/j.jcmg.2020.07.043
– ident: e_1_3_2_14_2
  doi: 10.1161/CIRCULATIONAHA.116.021612
– ident: e_1_3_2_8_2
  doi: 10.1111/j.1523-1755.2004.00971.x
– ident: e_1_3_2_41_2
– ident: e_1_3_2_5_2
  doi: 10.1136/jnnp-2014-308724
– ident: e_1_3_2_15_2
  doi: 10.1016/j.jcmg.2022.06.013
– ident: e_1_3_2_17_2
  doi: 10.1016/j.jaccas.2020.11.036
– ident: e_1_3_2_31_2
  doi: 10.1002/ehf2.12989
– ident: e_1_3_2_34_2
  doi: 10.1016/j.jacc.2013.02.059
– ident: e_1_3_2_47_2
  doi: 10.1161/CIRCIMAGING.123.015243
– ident: e_1_3_2_36_2
  doi: 10.1161/HCI.0000000000000030
– ident: e_1_3_2_43_2
  doi: 10.1002/acn3.51328
– ident: e_1_3_2_23_2
  doi: 10.1007/s40120-021-00235-6
– ident: e_1_3_2_27_2
  doi: 10.1253/circj.CJ-20-0110
SSID ssj0000627359
Score 2.4139802
Snippet Hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may serve as a...
Background Hereditary transthyretin amyloid cardiomyopathy (hATTR‐CM) is a progressive and fatal disease. Recent evidence indicates that bone scintigraphy may...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e030512
SubjectTerms 99mTc‐pyrophosphate
eplontersen
hereditary transthyretin amyloidosis
Original Research
single‐photon emission computed tomography/computed tomography
SummonAdditionalLinks – databaseName: Directory of Open Access Journals - May need to register for free articles
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Ni9swEBVlD6WX0u-mX6jQQy_eyLYsW8d0yRIWtiw0oXszkiURQ2KH2Dn41p-wv2-P_SWdsbxpUrb00osPsoyF51nzZiS9IeRTqBNlM1YEkXAi4KoQQSaNCnhmYqEU42m_iebyq5gt-MV1cn1Q6gv3hHl5YP_hxoYLKzVAR4MnUriOZWTkkgIcWcJEpnH2BZ93EEz5ORjcciIHLR9gNeOLyQwTf_EpIjyMjtxQr9Z_H8X8c6fkges5f0IeD5yRTvxYn5IHtnpGHl4Oq-LPye2isbR2tE-T27bcrX_-uJESr1fdtt4s62azBE5Jv4GfWllsXtbA-egUjIzZMjrUdjB0Xq8HDevxPW20rKifBDAbSOe_z25Rf0qhwWFMNyuUvNo2tsIHrrxya0O_l-2SzrA2aNmqbUd7Nwk4wXOUFZ2su1VdGnrWb5BddzXWSu5ekMX5dH42C4aaDUHBBWshEtXOFU5yxk2KSSqnY6N4VkTMMuN4onQRSW1dHFqdOcsYgCi0hZbADCFail-Sk6qu7GtClbWSGeEiizEbMKlCMpcaFytrNI_CETm9M2FeDILmWFdjlfeBjQhztHkONs-9zUfk8_6Bjdfy-HvXL4iJfTcU4e4bAJr5AM38X9AckY93iMrBnrgSoypb75o8QlX-FMg4vOiVR9j-VXGGKnhpOiLZEfaOxnJ8pyqXvTB4yGQkMha_-R-jf0seRUDgMN0UinfkpN3u7HsgYK3-0P9rvwAC5Ta5
  priority: 102
  providerName: Directory of Open Access Journals
Title Use of Technetium‐99m‐Pyrophosphate Single‐Photon Emission Computed Tomography/Computed Tomography in Monitoring Therapeutic Changes of Eplontersen in Patients With Hereditary Transthyretin Amyloid Cardiomyopathy
URI https://www.ncbi.nlm.nih.gov/pubmed/38214277
https://www.proquest.com/docview/2915571152
https://pubmed.ncbi.nlm.nih.gov/PMC10926803
https://doaj.org/article/d46e9b051b124a0385d92f5c1905068b
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Ni9swEBVlC6WX0u-mH4sKPfTirGwrsn0oJV2yhIWUQBO6NyNZUmNI7KztQP0_9wftjOzNNiWFXm3ZEp6R581Ieo-QT74aSROzzAuEFR6XmfDiREuPxzoUUjIeuU00s-9iuuSXV6Orezmg_gPWR1M71JNaVuvh7-v2K0z4L27CC__scjzFml44ROdFxeGHEJYilDOY9Vi_-y1DpHbiaQGyE0CawXqqnyPvOIhSjsz_GAL9eyPlH5Hp4il50kNKOu584Bl5YIrn5NGsXzR_QW6WtaGlpa6Kbpp8t4Fhbbx5W5XbVVlvVwA36Q8IYWvjzVclgEE6AetjGY32og-aLspNT259duQazQva_R2wTEgX94e6aHd8ocYBTLZr5MKqalPgA_OO0rWmP_NmRacoGpo3smqpi5_gQHjAsqDjTbsuc03P3c7ZTVuiiHL7kiwvJovzqdeLOXgZF6yBFFVZm9mEM64jrF5ZFWrJ4yxghmnLR1JlQaKMDX2jYmsYA-_yTaYSgIyQRoWvyElRFuYNodKYhGlhA4PJHECsLGE20jaURise-AMyvDNemvVM5yi4sU5dxiP8FK2dgrXTztoD8nn_wLYj-fh302_oDftmyM7tLpTVr7Sf7KnmwiQKmitATxLXXnUS2FEG4GvERKwG5OOdL6VgT1yikYUpd3UaIF1_BCgdOnrd-da-qzBGerwoGpD4wOsOxnJ4p8hXjjHcZ0kgYha-_Y-O35HHAQA3LDP54j05aaqd-QDAq1GnrmBx6qbVLQp3MWY
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Use+of+Technetium-99m-Pyrophosphate+Single-Photon+Emission+Computed+Tomography%2FComputed+Tomography+in+Monitoring+Therapeutic+Changes+of+Eplontersen+in+Patients+With+Hereditary+Transthyretin+Amyloid+Cardiomyopathy&rft.jtitle=Journal+of+the+American+Heart+Association&rft.au=Yu%2C+An-Li&rft.au=Chen%2C+Yi-Chieh&rft.au=Tsai%2C+Cheng-Hsuan&rft.au=Wu%2C+Yuan-Kun+Aden&rft.date=2024-01-16&rft.issn=2047-9980&rft.eissn=2047-9980&rft.volume=13&rft.issue=2&rft.spage=e030512&rft_id=info:doi/10.1161%2FJAHA.123.030512&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9980&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9980&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9980&client=summon